This study examined the antimicrobial ability of pure (99%) CBD and CBG, including their ability to inhibit the formation and cause the removal of biofilms, such as plaque on teeth. It was published in January 2023 in the International Journal of Molecular Sciences.
This in vitro study focused on determining the antimicrobial activity of CBD and CBG on human biofilms and skin-specific organisms associated with skin inflammation. They also studied whether these two cannabinoids negatively affected skin microbiota and whether they might work as a preservative for cosmetics.
Quotes from the authors:
Our results demonstrate that both molecules [CBD and CBG] present activity against planktonic bacteria and biofilms, with both cannabinoids removing mature biofilms
Our results indicate that CBG has a stronger antimicrobial potential than CBD.
Our results suggest that phytocannabinoids can be promising topical antimicrobial agents when searching for novel therapeutic candidates for different skin conditions.
the assays performed demonstrated that both CBD and CBG formulations are microbiota-friendly
Thus, we can assume that the development of topical formulations with active concentrations of CBG and/or CBD might represent a promising approach to tackle skin conditions where microorganisms and inflammation play a fundamental role, including psoriasis, atopic dermatitis, and acne.
The full text article is here at MDPI.com.